دورية أكاديمية
Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study
| العنوان: | Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study |
|---|---|
| المؤلفون: | Joana Freitas, José Silvano, Catarina Ribeiro, Jorge Malheiro, Sofia Pedroso, Manuela Almeida, Isabel Fonseca, La Salete Martins |
| المصدر: | Brazilian Journal of Transplantation, Vol 27 (2024) |
| بيانات النشر: | Associação Brasileira de Transplante de Órgãos, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Specialties of internal medicine LCC:Special situations and conditions LCC:Surgery |
| مصطلحات موضوعية: | Glucagon-like Peptide-1 Receptor Agonists, Kidney Transplant, Diabetes Mellitus, Specialties of internal medicine, RC581-951, Special situations and conditions, RC952-1245, Surgery, RD1-811 |
| الوصف: | Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes them appealing for use in this population, given their CV and renoprotective benefits. Nevertheless, there is insufficient substantial evidence regarding their efficacy in diabetic kidney transplant recipients (KTR). Methods: The objective of this retrospective study was to assess the effectiveness and safety of glucagon-like peptide agonists in KTR. The primary focus was to evaluate their impact on various parameters, such as hemoglobin A1c levels, body mass index (BMI), lipid panel, hemoglobin levels, renal allograft function (estimated glomerular filtration rate [eGFR]), and urinary protein-to-creatinine ratio. Results: During a median observation period of 18 months, this investigation included 64 renal transplant patients. Median eGFR at baseline was 61.9 mL/min/1.73 m2 and remained stable throughout the follow-up. Median HbA1c decreased from 7.5 to 7% (95%CI; p < 0.002). A significant improvement in BMI and lipid panel were also observed. We did not observed significant changes regarding median creatinine and urinary protein:creatinine ratio levels. No side effects justified discontinuation of the drug. Conclusion: This study shows that the use of glucagon-like peptide agonists is feasible and well-tolerated in KTR, with no significant side effects observed. Subsequent studies are needed to explore whether glucagonlike peptide agonists can effectively improve allograft survival in these patients. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English Spanish; Castilian Portuguese |
| تدمد: | 2764-1589 |
| العلاقة: | https://bjt.emnuvens.com.br/revista/article/view/563Test; https://doaj.org/toc/2764-1589Test |
| الوصول الحر: | https://doaj.org/article/8a1bd89554d04454af33627483c91aefTest |
| رقم الانضمام: | edsdoj.8a1bd89554d04454af33627483c91aef |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 27641589 |
|---|